New model links RNA editing glitch to early-stage type 1 diabetes

NewsGuard 100/100 Score

Hebrew University study proposes a new model suggesting that disrupted RNA editing within pancreatic beta cells might initiate an inflammatory response akin to early-stage type 1 diabetes. This new perspective challenges the long-held belief of viral involvement, offering potential implications for treatments and cures.

A recent study by researchers at the Hebrew University-Hadassah Medical School, Bar-Ilan University and Vanderbilt University has developed a new paradigm for early stages of type 1 diabetes (T1D), suggesting a new etiology that does not involve viral infection.

T1D is an autoimmune disease, affecting almost 10 million people worldwide, whereby the immune system attacks and destroys insulin-producing beta cells in the pancreas. In the absence of insulin, glucose concentration in blood increases, leading to a host of complications. Patients, typically diagnosed in childhood, require life-long treatment with insulin. A leading model for why T1D develops has been that the disease is initiated by viral infection, which on genetically-susceptible individuals is causing autoimmune attack on beta cells. This is supported by extensive information, for example the identification of an anti-viral response in early-stage disease. The implications of this view are vast; for example, it suggests the use of anti-viral therapy for preventing T1D. However, despite decades of search, a causal virus has not been found.

The research, led by Prof. Yuval Dor, Dr. Agnes Klochendler and MD/PhD students Ehud Knebel and Shani Peleg and published this week, introduces a new model for how T1D may develop, explaining the anti-viral response but with no need for viral infection.

The team studied a process called RNA editing, which acts to dismantle endogenous RNA molecules that fold on themselves, forming double-stranded RNA. Since double-stranded RNA is a hallmark of many viruses, such molecules can often be recognized, mistakenly, by the immune system as an indication of an invading virus, and trigger a detrimental immune response. They found that when RNA editing is defective in pancreatic beta cells, the body mounts a massive inflammatory attack, destroying beta cells and eventually leading to diabetes, with feature that strikingly resemble T1D.

Moreover, they discovered that high levels of blood glucose are boosting the inflammatory attack, suggesting a vicious cycle whereby beta cell destruction leads to diabetes which further drives destructive inflammation. Strikingly, independent work has recently discovered that genetically-inherited defects in RNA editing predispose people to multiple auto-inflammatory conditions, including T1D, suggesting relevance to actual human T1D.

Our research presents compelling evidence that disruption of RNA editing within beta cells can trigger an inflammatory response resembling early-stage type 1 diabetes. This offers a new view for how T1D may develop, with implications for prevention and treatment strategies".

Prof. Yuval Dor, Hebrew University-Hadassah Medical School, Bar-Ilan University

Dr. Agnes Klochendler added, "Identifying a link between natural double stranded RNA in beta cells, inflammation and diabetes opens a new perspective on T1D: a paradigm of "the enemy within", not necessitating external viral infection as the triggering event for this disease."

The Institute for Medical Research Israel-Canada (IMRIC) at the Hebrew University Faculty of Medicine is dedicated to pioneering biomedical research.

Source:
Journal reference:

Knebel, U. E., et al. (2023). Disrupted RNA editing in beta cells mimics early-stage type 1 diabetes. Cell Metabolism. doi.org/10.1016/j.cmet.2023.11.011.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Food additive emulsifiers linked to increased risk of type 2 diabetes